FDA approves Novartis' Tekturna for hypertension

WASHINGTON Novartis has received approval from the Food and Drug Administration for its application for Tekturna HCT.

Tekturna is a combination of aliskiren, a direct renin inhibitor, and hydrochlorothiazide, a thiazide diuretic. It will be available in 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg tablets.

Tekturna is indicated for the treatment of hypertension.